News | October 16, 2007

Sirolimus Stents Exacerbate Endothelial Injury after MI

October 17, 2007 - Compared to bare metal stents, in patients with acute myocardial infarction, sirolimus-eluting stent (SES) implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery, Japanese researchers report in the October 2nd issue of the Journal of the American College of Cardiology.

Kiyotaka Kugiyama, M.D., and colleagues at the University of Yamanashi, Chuo City note that drug-eluting stents reduce restenosis rates and revascularization but may impair recovery from reperfusion-induced endothelial injury.

To investigate, the researchers studied 29 patients with a first acute MI of the left anterior descending coronary artery (LAD). Thirteen had successful reperfusion therapy using an SES and the remaining 16 also had successful therapy employing a bare metal stent.

At two weeks, following intracoronary infusion of acetylcholine, the epicardial coronary artery became more severely restricted in the SES than the bare metal group. SES patients also had a lower increase in coronary blood flow in response to the agent.

In addition, levels of vascular endothelial growth factor (VEGF) in the anterior interventricular vein were significantly lower than in the aortic root in SES patients. This was not the case in the bare metal group.

The researchers stress that larger randomized studies are needed to confirm these findings. However, "these findings suggest that SES implantation may decrease the release of VEGF from the myocardial region supplied by the LAD, which may play a possible role in endothelial vasomotor dysfunction in infarct-related coronary arteries treated with SES."

Reference: J Am Coll Cardiol 2007;50:1305-1309

Source: Reuters


Related Content

News | Stents Drug Eluting

October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on ...

Home October 31, 2023
Home
News | Stents Drug Eluting

October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...

Home October 10, 2023
Home
News | Stents Drug Eluting

July 13, 2023 — Elixir Medical, a developer of breakthrough cardiovascular technologies, announced enrollment completion ...

Home July 13, 2023
Home
News | Stents Drug Eluting

July 12, 2023 — In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study ...

Home July 12, 2023
Home
News | Stents Drug Eluting

May 25, 2023 — First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic ...

Home May 25, 2023
Home
News | Stents Drug Eluting

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent ...

Home January 02, 2023
Home
News | Stents Drug Eluting

December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be ...

Home December 23, 2022
Home
News | Stents Drug Eluting

June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...

Home June 02, 2022
Home
News | Stents Drug Eluting

February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...

Home February 16, 2022
Home
News | Stents Drug Eluting

January 26, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's Synergy Megatron Drug ...

Home January 26, 2021
Home
Subscribe Now